Assertio Therapeutics (ASRT) Tops Q1 EPS by 5c

Assertio Therapeutics (NASDAQ: ASRT) reported Q1 EPS of $0.23, $0.05 better than the analyst estimate of $0.18. Revenue for the quarter came in at $59.7 million versus the consensus estimate of $55.28 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• Bernstein SocGen Group Upgrades X-Fab Silicon Foundries SE (XFAB:FP) to Outperform